Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pomalidomide Celgene

Celgene building

Celgene boosts CAR-T stake again with Bluebird Bio deal

The US biotech could receive $70m in development milestones for the candidate

Celgene building

Celgene bulks up pipeline again with $2.1bn Prothena deal

Acquires candidates with potential in Alzheimer’s, ALS and dementia

Celgene building

FDA turns down Celgene’s filing for multiple sclerosis drug

The application needs additional pharmacology information according to the US agency

- PMLiVE

Shaky mid-stage data won’t halt Celgene’s plans for Otezla

The US biotech will continue to test the drug in patients with UC and Behçet’s disease

Celgene building

Celgene’s triple multiple myeloma therapy clears phase III trial

The biotech says the combo hit its OPTIMISMM primary endpoint

Celgene’s CEO Mark Alles is appointed as chairman

He succeeds Bob Hugin who is retiring from the pharma firm

- PMLiVE

Amgen set for Kyprolis label boost after CHMP backing

Multiple myeloma treatment set to add new survival data

Celgene building

Celgene reaches $9bn agreement to buy Juno

Acquires its blood cancer CAR-T candidate in the process

- PMLiVE

Unsure on efficacy, NICE passes J&J’s Darzalex to CDF

The bone marrow cancer therapy is now temporarily approved as a fourth-line treatment

Celgene building

Is acquisitive Celgene now eyeing CAR-T specialist Juno?

Rumours circulate just days after the US biotech confirms ImpactBio purchase

Celgene building

Celgene boosts haematology pipeline with $7bn Impact Bio deal

Acquiring Sanofi’s rejected fedratinib candidate as part of the process

J&J launches digital skincare challenge

Seeks start-ups focused on tackling areas such as skin health adherence treatment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links